Drug Trial Radar · NCT07018752
A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Aug 20, 2025
Primary completion
Apr 2028
Study completion Jan 2030
Sponsor
- Lead sponsor
- The Lymphoma Academic Research OrganisationAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- iOnctura; AbbVie; Bristol-Myers Squibb
- First posted
- Jun 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a platform trial for the evaluation of new drugs or combination of drugs in relapsed or refractory peripheral T-cell lymphomas. The objective of the study is to generate exploratory data on new drugs or combination of drugs to treat refractory/relapse peripheral T-cells lymphoma to better identify the population of interest and design future correct clinical trials. Primary objectives of the different sub-studies : * phase 1 sub-studies: determine the safety and tolerability of escalating doses of the sub-study treatment * phase 2 sub-studies: identify drugs that will improve significantly the outcome in target patients Secondary objectives of all sub-studies: analyze the response rate, the clinical benefit rate, the progression-free survival, the duration of response, the time to next treatment or death, the overall survival, the rate of transplantation following study treatment and the safety profile of the drugs used
Conditions
- Peripheral T Cells Lymphoma (PTCL)
- Follicular Helper T-Cell Lymphoma
Interventions
roginolisibDrug
Roginolisib daily intake
golcadomideDrug
Golcadomide daily intake
azacitidineDrug
oral 5-azacitidine daily intake
VenetoclaxDrug
Venetoclax daily intake
Primary outcomes
What the sponsor says the trial is designed to measure.
- Modified Progression-Free SurvivalTime frame: From enrollment to end of follow-up period of Origina-ly-T (= maximum 2 years after enrollment)
- Maximum Tolerated DoseTime frame: From enrollment to end of treatment of sub-study GolcAza (= maximum 2 years from enrollment)
- Recommended Phase II DoseTime frame: From enrollment to end of treatment of sub-study GolcAza (= maximum 2 years from enrollment)
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
CHU D'ANGERS - Service des Maladies du Sang
Angers, France · Recruiting
Institut d'Hématologie de Basse Normandie - Service Hématologie (CHU Hôpital Côte de Nacre)
Caen, France · Recruiting
CHU Estaing - Service Thérapie Cellulaire et Hématologie Clinique
Clermont-Ferrand, France · Recruiting
Hôpital Henri Mondor - Unité Hémopathies Lymphoïdes
Créteil, France · Recruiting
CHU Dijon Bourgogne - Service Hématologie Clinique
Dijon, France · Recruiting
CHU de Grenoble - Service Hématologie
La Tronche, France · Recruiting
CH du Mans - Centre de Cancérologie de la Sarthe - Service Hématologie
Le Mans, France · Recruiting
CHU de Lille - Hôpital Claude Huriez - Service des Maladies du Sang
Lille, France · Recruiting
Institut Paoli Calmettes - Service Hématologie
Marseille, France · Not yet recruiting
CHU de Montpellier - Département d'Hématologie Clinique
Montpellier, France · Recruiting
CHU de Nantes - Service Hématologie
Nantes, France · Recruiting
Hôpital Necker - Service Hématologie Adultes
Paris, France · Recruiting
CHU de Bordeaux - Hôpital Haut-Lévêque - Centre François Magendie - Service d'Hématologie et Thérapie Cellulaire
Pessac, France · Recruiting
CHU Lyon-Sud - Hématologie Clinique
Pierre-Bénite, France · Recruiting
CHU de Poitiers - Hôpital de la Milétrie - Service d'Oncologie Hématologique et Thérapie Cellulaire
Poitiers, France · Recruiting
CHU Pontchaillou - Hématologie Clinique
Rennes, France · Recruiting
Centre Henri Becquerel - Service Hématologie
Rouen, France · Recruiting
Institut de Cancérologie et d'Hématologie Universitaire de Saint-Étienne - Service Hématologie
Saint-Etienne, France · Recruiting
CH de la Côte Basque - Service Hématologie
Saint-Jean-de-Luz, France · Recruiting
CHRU Nancy - Hôpital Brabois - Service Hématologie
Vandœuvre-lès-Nancy, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.